# C_2017259EN.01000901.xml

| 9.8.2017 | EN | Official Journal of the European Union | C 259/9 |
| --- | --- | --- | --- |

9.8.2017

EN

Official Journal of the European Union

C 259/9

---

Prior notification of a concentration

(Case M.8572 — Pamplona Capital/Parexel)

Candidate case for simplified procedure

(Text with EEA relevance)

(2017/C 259/05)

| 1. | On 1 August 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Pamplona Capital (UK) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Parexel International Corporation (USA) by way of a purchase of shares. |
| --- | --- |

1.

On 1 August 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Pamplona Capital (UK) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Parexel International Corporation (USA) by way of a purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:
  —   For Pamplona Capital: global private equity investment, providing an investment platform across private equity, fund of hedge funds and single manager hedge fund investments.
  —   For Prexel International Corporation: biopharmaceutical outsourcing services, providing a broad range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization and advanced technology products and services to the worldwide pharmaceutical, biotechnology and medical device industries. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   For Pamplona Capital: global private equity investment, providing an investment platform across private equity, fund of hedge funds and single manager hedge fund investments.

For Pamplona Capital

—   For Prexel International Corporation: biopharmaceutical outsourcing services, providing a broad range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization and advanced technology products and services to the worldwide pharmaceutical, biotechnology and medical device industries.

For Prexel International Corporation

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in this Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in this Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8572 — Pamplona Capital/Parexel, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8572 — Pamplona Capital/Parexel, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---